Pfizer (PFE) is back in focus after the FDA accepted a Priority Review for its supplemental New Drug Application for TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer.

Pfizer’s latest oncology update lands after a mixed stretch for the stock, with the share price at US$24.54, a 1-month share price return of 1.03% but a 90-day decline of 7.33%. The 1-year total shareholder return of 8.03% contrasts with weaker 3 and 5-year total shareholder returns, suggesting shorter term momentum has picked up slightly as investors reassess risk and income potential around its pipeline, legal disputes and high dividend yield.

If this prostate cancer update has you thinking about where healthcare and AI intersect next, it could be worth scanning 40 healthcare AI stocks.

After a modest recent bounce but weaker multi year returns, the question with Pfizer at about US$24.50 is whether you lean into today’s yield and oncology newsflow, or hold out for an even cheaper entry as the valuation stacks up next.

Most Popular Narrative: 16% Undervalued

On the latest narrative view, Pfizer’s fair value of about $29.19 sits above the current $24.54 share price. This puts the focus firmly on how its pipeline and margins are expected to evolve from here.

Strategic business development and licensing (such as the 3SBio bispecific antibody deal and ongoing portfolio additions in high-value areas like oncology, immunology, and obesity) support revenue diversification and lifecycle management, mitigating the impact of patent expirations and increasing net margins via synergies and optimized product mix.

Curious what earnings path and margin rebuild are baked into that fair value for Pfizer? The narrative leans on falling sales, fatter margins, and a richer future earnings multiple. Want to see which specific revenue and profit assumptions are doing the heavy lifting behind that $29.19 figure?

Result: Fair Value of $29.19 (UNDERVALUED)

However, this Pfizer narrative could be knocked off course if the projected revenue decline accelerates or if key patent expiries erode earnings faster than expected.

Next Steps

If this mix of opportunity and concern around Pfizer has you on the fence, consider acting soon to weigh both sides and ground your own view with 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

Do not stop at Pfizer alone; broaden your watchlist now with focused stock ideas that line up with the way you like to invest.

• Target resilient income by scanning companies we flag as potential yield standouts through the 9 dividend fortresses.
• Hunt for quality at a reasonable price by running the 50 high quality undervalued stocks before the crowd catches on.
• Spot companies with stronger financial footing by filtering through the solid balance sheet and fundamentals stocks screener (49 results) while opportunities are still underfollowed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.